23/07/2025
Advancing care, reducing burden. 🩺💊
Pinnacle Life Science proudly announces the successful completion of the Pilot BE Study for Enzalutamide 80 mg, developed using a Non-Infringing Formulation—marking a significant step forward in innovation with integrity.
Here’s why it matters:
📌 Therapeutic Significance
• Enzalutamide is a clinically proven androgen receptor inhibitor used in mCRPC & nmCRPC.
• It plays a vital role in improving survival and delaying disease progression.
📌 Patient-Centric Value
The 80 mg strength reduces pill burden, improving treatment adherence and patient quality of life.
📌 Advancing Global Cancer Care
This milestone reinforces Pinnacle Life Science’s commitment to delivering high-quality, accessible, and compliant oncology solutions to address the global burden of prostate cancer.